<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609452</url>
  </required_header>
  <id_info>
    <org_study_id>AN-ITP3321</org_study_id>
    <nct_id>NCT01609452</nct_id>
  </id_info>
  <brief_title>MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP</brief_title>
  <official_title>MONICA-SC: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With Immune Thrombocytopenic Purpura (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anthera Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when
      administered on top of standard-of-care to subjects with Immune Thrombocytopenic Purpura
      (ITP).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of a durable platelet response of 50 billion platelets per liter or higher over the last weeks of treatment.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of a durable platelet count of 50 billion platelets per liter or higher over the last weeks of treatment under conditions of decreased concomitant steroid medication.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of a transient improvement in platelet count of 50 billion platelets per liter or higher at any 4 weeks of the treatment period.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in background corticosteroid dose.</measure>
    <time_frame>baseline to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects requiring rescue therapy.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bleeding risk.</measure>
    <time_frame>baseline to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile (AEs, vitals signs, labs)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker changes from baseline.</measure>
    <time_frame>baseline to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Immune Thrombocytopenic Purpura</condition>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Blisibimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blisibimod</intervention_name>
    <arm_group_label>Blisibimod</arm_group_label>
    <other_name>A-623</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 75 years of age(male or female).

          2. Diagnosis of ITP according to the guidelines of the American Society of Hematology
             (ASH) and British Committee for Standards in Hematology.

          3. Platelet counts at Screening of 30 billion/L or less for subjects not on ITP
             medication, or 50 billion/L or less for subjects receiving stable background ITP
             medication.

        Exclusion Criteria:

          1. Subjects who have had a splenectomy for any reason.

          2. Currently receiving high-dose ITP medications, eltrombopag, romiplostim, rituximab, or
             investigational therapeutic agents.

          3. Nursing or pregnant.

          4. Active infection requiring hospitalization or treatment with parenteral antibiotics
             within the past 60 days.

          5. Any known history of bone marrow stem cell disorder.

          6. Active hepatitis B, active hepatitis C or a documented history of HIV, hepatitis B, or
             hepatitis C.

          7. Liver disease.

          8. Malignancy within the past 5 years.

          9. History of active tuberculosis (TB) or history of TB infection.

         10. Subject has not yet completed at least 3 months or 5 half-lives (whichever is longer)
             since ending other investigational study.

         11. History of congenital immunodeficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2012</study_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune Thrombocytopenic Purpura</keyword>
  <keyword>Idiopathic Thrombocytopenic Purpura</keyword>
  <keyword>Chronic ITP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

